Vertex Pharmaceuticals (VRTX) Q2 FY26 earnings call: guidance and Q&A

What signal led to the 80mg dose selection for Pove in pMN Phase III, and what are the current bottlenecks for JOURNAVX regarding formulary and payer dynamics?

The DSMB selected the 80mg dose for Pove in pMN Phase III based on efficacy (PLA2R reduction) and safety data, consistent with prior RUBY-3 results. For JOURNAVX, prescription growth and hospital adoption are strong, but ongoing work is needed to secure final access elements and educate physicians on quantity limits/prior authorizations to reduce reliance on the PSP program.

“The DSMB was asked to base their decision and it was their decision because we do not have access to the unblinded data to look at on efficacy PLA2R, which is the biomarker equivalent in membranous as Gd-IgA1 is to IgAN.”

asked by Salveen Richter · answered by Reshma Kewalramani

What clinical attributes are sought for VX-828 and other next-gen CF assets, and what are the perspectives on DPN for JOURNAVX from payer/physician discussions?

For next-gen CF assets, Vertex seeks improved efficacy (more patients to <30 millimoles sweat chloride) and safety, while maintaining once-daily dosing and good DDI profiles. Regarding JOURNAVX in DPN, the company has been hyper-focused on acute pain and will provide more details on DPN perspectives in coming months.

“We are looking for potential improvement in efficacy, i.e., more people who can get down to less than 30 millimoles. And of course, we're looking for safety as well.”

asked by Geoffrey Meacham · answered by Reshma Kewalramani

Do you expect material differentiation on eGFR across new IgAN products, and over what time horizon would it become apparent?

Good proteinuria reductions should lead to GFR stabilization. Real differentiation between IgAN products will be seen in time to ESRD (dialysis, transplantation, or death), with medicines achieving stronger reductions in proteinuria, hematuria, and Gd-IgA1 more likely to show improved long-term outcomes.

“I do expect that the medicine that has the stronger reductions in proteinuria, the medicine that gets more patients to less than 0.5 or 0.3, better improvements in hematuria and Gd-IgA1 are more likely to have an improved profile when it comes to that ultimate endpoint.”

asked by Jessica Fye · answered by Reshma Kewalramani

What data would be necessary in the AMPLITUDE interim analysis to file for accelerated approval?

The agreement with the FDA for potential accelerated approval based on the interim analysis of the AMPLITUDE study is centered on the 1-year GFR endpoint.

“The agency has provided and we have an agreement with the agency for a potential accelerated approval based on the primary endpoint at the time of the IA, which is 1 year GFR.”

asked by Cory Kasimov · answered by Reshma Kewalramani

How do you see acute pain dynamics with additional NaV1.8 entrants, and what is the potential impact to launch timing if zimi filing is synced with VX-017?

Vertex is confident in JOURNAVX's position in the acute pain market, noting high industry appetite for non-opioids. For T1D, the company is working to accelerate the VX-017 (Type O) program to launch first or very close to zimislecel (Type A), with updated plans and timelines expected in H2 2026.

“We are considering options to further streamline our regulatory strategy and commercialization approach. We expect to provide updated T1D plans, including time lines later this year.”

asked by Brian Abrahams · answered by Reshma Kewalramani

How do you compare your Pove IgAN data and launch strategy to recent competitor eGFR data?

Competitor eGFR data showing stabilization is consistent with expected outcomes from proteinuria reduction. Vertex believes Pove's strong proteinuria (52% reduction), hematuria, and Gd-IgA1 reductions, combined with patient-centric once-monthly auto-injector delivery, position it strongly for launch.

“I see us putting up very strong numbers on proteinuria, numerically, the best out there, 52% change from baseline in terms of proteinuria reduction, 70-plus percent reductions in hematuria and 70-plus percent reductions in Gd-IgA1.”

asked by Michael Yee · answered by Reshma Kewalramani

How will Vertex interpret upcoming competitor data for CFTR modulators, specifically regarding sweat chloride reductions?

The bar for next-gen CFTR modulators is exceptionally high, given ALYFTREK's ability to get two-thirds of patients to less than 30 millimoles sweat chloride. Any new medicine must get more patients to this carrier threshold, along with a strong safety, tolerability, and once-daily dosing profile, to be competitive.

“I think that the bar is exceptionally high and rests on getting more patients to less than 30 millimoles. That is the mark and that's the mark that we or anyone else has to hit in order to have a competitive medicine.”

asked by Philip Nadeau · answered by Reshma Kewalramani

What are the expectations for the upcoming AMPLIFIED Phase II trial, and how does it read through to AMPLITUDE?

The AMPLIFIED study, which includes expanded AMKD populations (diabetes, modest proteinuria), will provide learning on whether proteinuria can be reduced in these different groups. These populations were intentionally kept separate from the pivotal AMPLITUDE study, which focuses on core AMKD patients with moderate-to-heavy proteinuria.

“These are questions worth studying, but there are clearly different populations than AMPLITUDE, which is why we specifically did not include them in the Phase II original study of inaxaplin and equally why we didn't include them in the Phase III study called AMPLITUDE.”

asked by Terence Flynn · answered by Reshma Kewalramani